For the quarter ended December 2024, Myriad Genetics (MYGN) reported income of $210.6 million, up 7.1% over the identical interval final 12 months. EPS got here in at $0.03, in comparison with $0.04 within the year-ago quarter.
The reported income compares to the Zacks Consensus Estimate of $210.14 million, representing a shock of +0.22%. The corporate has not delivered EPS shock, with the consensus EPS estimate being $0.03.
Whereas buyers scrutinize income and earnings adjustments year-over-year and the way they evaluate with Wall Avenue expectations to find out their subsequent transfer, some key metrics at all times provide a extra correct image of an organization’s monetary well being.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps buyers undertaking a inventory’s worth efficiency extra precisely.
Right here is how Myriad carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Avenue analysts:
- Check volumes: 374,000 versus 384,314 estimated by two analysts on common.
- Income by Product- Hereditary Most cancers: $94.30 million versus $92.29 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +6.1% change.
- Income by Product- Pharmacogenomics: $40.60 million versus the three-analyst common estimate of $42.58 million. The reported quantity represents a year-over-year change of +14%.
- Income by Product- Tumor Profiling: $30.80 million in comparison with the $33.93 million common estimate based mostly on three analysts. The reported quantity represents a change of -4.1% 12 months over 12 months.
- Income by Product- Prenatal: $44.90 million in comparison with the $44.75 million common estimate based mostly on three analysts. The reported quantity represents a change of +12.3% 12 months over 12 months.
View all Key Company Metrics for Myriad here>>>
Shares of Myriad have returned +10.6% over the previous month versus the Zacks S&P 500 composite’s -0.5% change. The inventory at the moment has a Zacks Rank #4 (Promote), indicating that it might underperform the broader market within the close to time period.
Simply Launched: Zacks High 10 Shares for 2025
Hurry – you may nonetheless get in early on our 10 high tickers for 2025. Handpicked by Zacks Director of Analysis Sheraz Mian, this portfolio has been stunningly and persistently profitable. From inception in 2012 by November, 2024, the Zacks High 10 Shares gained +2,112.6%, greater than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed by 4,400 firms coated by the Zacks Rank and handpicked the most effective 10 to purchase and maintain in 2025. You’ll be able to nonetheless be among the many first to see these just-released shares with monumental potential.
Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
